上海谊众：预计2025年净利润增长819.42%至6413万元，核心产品紫杉醇胶束销量提升

Core Viewpoint - The company Shanghai Yizhong expects to achieve a revenue of 317 million yuan in 2025, representing an increase of 82.72%, and a net profit attributable to shareholders of 64.13 million yuan, reflecting a growth of 819.42% [1] Group 1: Revenue and Profit Growth - The projected revenue growth is primarily driven by the inclusion of the core product, paclitaxel micelles, in the national medical insurance catalog [1] - The expected net profit growth is significantly influenced by the company's ongoing investment in research and development, which is advancing multiple innovative drug projects [1] Group 2: Cost Management and Efficiency - The company has implemented refined management of sales and administrative expenses, achieving reasonable spending and effective control [1] - This approach has allowed the company to maintain substantial research and development investments while simultaneously reducing costs and increasing efficiency, leading to significant year-on-year growth in revenue and operating profit [1]